stockrow
Saturday 7 November 2026
Export NTLA’s income statement to Excel — free account
Intellia Therapeutics, Inc.
NTLA Healthcare Biotechnology
Intellia Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $67.7 million, up 16.9% from fiscal 2024.
- Revenue
- −48.0%
- EPS
- +1.09%
- Free cash flow
- −11.1%
Quarter to September 2026, against a year earlier
11.35
0.25
+2.25%
Follow NTLA
Alert me
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
— | 3 | 3 | 3 | 4 | 2 | 4 | 2 | 3 | 4 |
Altman Z-Score |
2.42 | 5.53 | 4.48 | 5.19 | 11.74 | 18.96 | 4.48 | 4.23 | (1.29) | (1.93) |
P/S ratio |
18.18 | 29.65 | 19.32 | 16.08 | 52.52 | 253.61 | 54.00 | 76.86 | 19.91 | 14.40 |
Altman Z″-Score (non-manufacturers) |
6.66 | 7.52 | 5.93 | 4.31 | 5.61 | 4.40 | 4.71 | 2.03 | (3.19) | (6.12) |
P/FCF ratio |
10.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
(20.79) | (36.35) | (68.86) | (24.18) | (75.71) | (153.38) | (31.32) | (29.96) | (13.53) | (14.06) |
Beneish M-Score |
(0.58) | (2.08) | (3.19) | (0.82) | (3.39) | (0.68) | (2.35) | 8.70 | (2.94) | (2.68) |
P/B ratio |
1.43 | 2.58 | 2.12 | 2.57 | 5.78 | 8.06 | 2.28 | 2.65 | 1.32 | 1.45 |
Price to Tangible BV |
1.43 | 2.58 | 2.12 | 2.57 | 5.78 | 8.06 | 2.28 | 2.65 | 1.32 | 1.45 |
EV/Sales |
1.61 | 16.61 | 9.00 | 9.59 | 42.22 | 230.96 | 31.12 | 51.71 | 9.52 | 7.75 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
0.73 | (6.65) | (4.47) | (4.00) | (49.05) | (33.92) | (4.87) | (4.76) | (1.58) | (1.33) |
EV/FCF |
0.88 | (5.76) | (4.06) | (3.76) | (45.77) | (32.10) | (4.68) | (4.60) | (1.55) | (1.32) |
Quick Ratio |
9.10 | 11.20 | 7.93 | 7.98 | 9.33 | 5.97 | 9.45 | 8.23 | 5.50 | 4.42 |
Current Ratio |
9.15 | 11.32 | 8.01 | 8.12 | 9.60 | 6.11 | 9.61 | 8.67 | 5.77 | 5.08 |
Net Debt/EBITDA |
8.79 | 5.12 | 3.63 | 2.78 | 4.59 | 2.87 | 2.65 | 1.80 | 1.15 | 1.06 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.09 | 0.08 | 0.08 | 0.13 | 0.11 | 0.03 | 0.04 | 0.03 | 0.05 | 0.07 |
Operating CF/Net income |
(1.14) | 0.97 | 0.72 | 1.04 | 0.37 | 0.84 | 0.70 | 0.82 | 0.67 | 0.96 |
Capex/Depreciation |
(5.58) | (3.37) | (1.39) | (1.22) | (0.57) | (1.85) | (1.77) | (1.56) | (0.56) | (0.07) |
| (33.54%) | (26.46%) | (29.50%) | (36.34%) | (33.69%) | (34.18%) | (41.67%) | (42.10%) | (54.00%) | (53.48%) | |
| (16.60%) | (20.01%) | (23.59%) | (29.21%) | (26.56%) | (27.19%) | (33.69%) | (34.11%) | (41.66%) | (40.60%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (57.42%) | (666.53%) | (233.47%) | (123.47%) | (124.43%) |
Return on Tangible Assets |
(12.11%) | (19.94%) | (28.31%) | (36.61%) | (23.62%) | (40.32%) | (42.41%) | (52.54%) | (93.28%) | (93.48%) |
Average Days of Receivables |
142.95 | 146.34 | 90.51 | 39.12 | 13.41 | 22.43 | 26.39 | 366.82 | 53.71 | 51.07 |
Research and Development Expense of Revenue |
193.22% | 259.02% | 292.81% | 251.52% | 259.35% | 695.27% | 805.78% | 1,199.36% | 805.69% | 574.63% |
Selling, General and Administrative Expense of Revenue |
101.94% | 107.31% | 105.77% | 95.26% | 76.16% | 215.10% | 173.26% | 321.15% | 217.41% | 177.03% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
40.75% | 58.67% | 56.01% | 35.01% | 34.32% | 142.22% | 175.36% | 369.54% | 266.55% | 118.54% |
Graham Net Nets |
0.64 | 0.36 | 0.43 | 0.32 | 0.15 | 0.06 | 0.33 | 0.27 | 0.28 | 0.37 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(80.01%) | (8.65%) | (14.58%) | (14.38%) | (4.41%) | (3.18%) | (17.84%) | (17.55%) | (45.03%) | (42.60%) |
Free Cash Flow Yield |
10.00% | (9.73%) | (11.48%) | (15.88%) | (1.76%) | (2.84%) | (12.32%) | (14.64%) | (30.77%) | (40.63%) |
Revenue per Share |
0.74 | 0.73 | 0.71 | 0.91 | 1.04 | 0.47 | 0.68 | 0.41 | 0.59 | 0.62 |
Operating CF per Share |
1.62 | (1.81) | (1.42) | (2.19) | (0.89) | (3.17) | (4.33) | (4.44) | (3.53) | (3.64) |
Capex per Share |
(0.28) | (0.28) | (0.14) | (0.14) | (0.06) | (0.18) | (0.17) | (0.16) | (0.06) | (0.01) |
Free Cash Flow per Share |
1.35 | (2.09) | (1.57) | (2.33) | (0.96) | (3.35) | (4.50) | (4.60) | (3.59) | (3.65) |
Cash per Share |
12.29 | 9.46 | 7.29 | 5.92 | 10.67 | 10.56 | 15.49 | 10.28 | 6.09 | 4.15 |
Shareholders Equity per Share |
9.44 | 8.35 | 6.45 | 5.71 | 9.41 | 14.67 | 16.05 | 11.83 | 8.82 | 6.20 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
9.44 | 8.35 | 6.45 | 5.71 | 9.41 | 14.67 | 16.05 | 11.83 | 8.82 | 6.20 |
Free Cash Flow |
29.94 | (75.37) | (67.48) | (110.03) | (53.50) | (237.79) | (346.69) | (408.07) | (354.66) | (395.86) |
Working Capital |
250.58 | 323.47 | 284.41 | 253.85 | 552.26 | 643.47 | 1,090.24 | 883.12 | 529.01 | 423.83 |
Capital Expenditures |
(6.16) | (10.09) | (6.23) | (6.79) | (3.58) | (12.76) | (13.41) | (13.98) | (5.78) | (1.13) |
Net Current Asset Value |
192.17 | 279.19 | 255.58 | 225.08 | 467.27 | 515.08 | 932.27 | 747.52 | 320.80 | 356.98 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.37 | 0.39 | 0.20 | 0.16 | 0.06 | 0.39 | 0.26 | 0.39 | 0.10 | 0.02 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.10 | 0.20 | 0.26 | 0.31 | 0.40 | 0.33 | 0.27 | 0.27 | 0.38 | 0.90 |
Cash ROIC |
6.20% | (11.75%) | (11.40%) | (20.02%) | (4.76%) | (13.29%) | (14.28%) | (20.79%) | (24.07%) | (35.30%) |
Accounts Receivable Turnover |
4.42 | 3.09 | 3.38 | 7.09 | 17.18 | 15.89 | 17.98 | 1.80 | 2.57 | 7.53 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | — | — | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | — | — | 0.00 | 0.00 | — | — | — |
Average Receivables |
3.73 | 8.46 | 9.01 | 6.08 | 3.38 | 2.08 | 2.90 | 20.11 | 22.49 | 8.99 |
Average Payables |
3.01 | 3.41 | 2.44 | 3.32 | 7.20 | 10.06 | 7.40 | 6.30 | 11.02 | 17.42 |
Average Assets |
190.55 | 337.60 | 361.78 | 340.80 | 505.30 | 985.39 | 1,407.29 | 1,410.55 | 1,246.00 | 1,016.57 |
Average Common Equity |
94.32 | 255.22 | 289.26 | 273.90 | 398.48 | 783.66 | 1,137.91 | 1,142.88 | 961.06 | 771.68 |
Columns are period end dates · fundamentals updated 5 Nov 2026